

Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Giulio Cabrini**
Address(es) 10, Via San Leonardo, I-37128, Verona, Italy
Telephone(s) (+39-045) 812 2457
Fax(es) (+39-045) 812 2840
E-mail(s) giulio.cabrini@univr.it
Nationality Italiana
Date of birth 01/03/1954
Gender Maschio



Mobile (+39) 349 34 12 028

Work experience

Dates	01/07/2017 - oggi
Occupation or position held	Collaboratore alla Ricerca
Main activities and responsibilities	Consulenza scientifica su progetti di ricerca
Name and address of employer	Università di Verona, IT - Dipartimento di Neuroscienze, Biomedicina e Movimento - Strada Le Grazie, 37134 Verona, IT
Type of business or sector	Ricerca biomedica
Dates	01/03/1986 - 30/06/2017
Occupation or position held	Responsabile Laboratorio di Patologia molecolare
Main activities and responsibilities	Co-fondatore e Responsabile, Laboratorio di Patologia Molecolare afferente al Centro Fibrosi Cistica di Verona e dal 2006 afferente al Dipartimento di Patologia e Diagnostica (Ospedale Universitario di Verona, IT). <i>Group leader</i> di progetti di ricerca sperimentale in biomedicina, principalmente sulla malattia genetica fibrosi cistica: patologia molecolare e meccanismi del difetto genetico, sviluppo di approcci pre-clinici di trasferimento genico e identificazione di molecole organiche da applicare come terapie innovative di correzione del difetto genetico di base. Ricerca pre-clinica sui tumori maligni (gliomi). Professore a contratto e <i>Tutor</i> presso le Università degli Studi di Ferrara e di Verona (dal 1995).
Name and address of employer	Azienda Ospedaliera Universitaria Integrata Verona - Piazzale Stefani 1 - 37126 Verona, IT
Type of business or sector	Ricerca biomedica
Dates	01/02/1985 - 28/02/1986
Occupation or position held	Ricercatore ospite (<i>Visiting scientist</i>)
Main activities and responsibilities	Ricerca sperimentale di biochimica e biofisica delle membrane cellulari presso <i>Laboratory of Membrane Biophysics, Cardiovascular Research Institute, UCSF</i> (gruppo Alan S. Verkman)
Name and address of employer	University of California San Francisco, Parnassus Avenue, San Francisco, CA, U.S.A.
Type of business or sector	Ricerca biomedica

Dates 01/01/1982 - 31/01/1985
 Occupation or position held Borsista
 Main activities and responsibilities Ricerca sperimentale in biomedicina, principalmente sul segnale transmembrana coinvolto nella risposta infiammatoria (gruppo Filippo Rossi)
 Name and address of employer Istituto di Patologia Generale, Università di Verona, Strada Le Grazie, 37134 Verona, IT
 Type of business or sector Ricerca biomedica

Dates 01/09/1979 - 31/12/1981
 Occupation or position held Borsista
 Main activities and responsibilities Attività clinica nel campo della pediatria presso il Centro Regionale Veneto Fibrosi Cistica (gruppo Gianni Mastella)
 Name and address of employer Istituti Ospitalieri di Verona, Piazzale Stefani 1, 37126 Verona, Italy
 Type of business or sector Medico

Education and training

Dates 1985 - 1989
 Title of qualification awarded Specialista in Biologia Clinica
 Principal subjects / occupational skills covered Biochimica, biologia molecolare e chimica clinica
 Name and type of organisation providing education and training Dipartimento di Biochimica, Università di Pavia, Pavia, IT

Dates 1979 - 1983
 Title of qualification awarded Specialista in Clinica pediatrica
 Principal subjects / occupational skills covered Differenti campi della pediatria
 Name and type of organisation providing education and training Dipartimento di Pediatria, Università di Padova, Padova, IT

Dates 1973 - 1979
 Title of qualification awarded Dottore in Medicina e Chirurgia
 Principal subjects / occupational skills covered Differenti campi della medicina e chirurgia
 Name and type of organisation providing education and training Facoltà di Medicina, Università di Padova, Padova, IT

Mother tongue(s) Italiano

Other language(s) English

Self-assessment
 European level (*)

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
B2	Independent user	B2	Independent user	B2	Independent user	B2	Independent user	B2	Independent user

(*) Common European Framework of Reference (CEF) level

Additional information

Principali interessi scientifici e principali traguardi raggiunti

Dal 1986, dopo aver fondato il Laboratorio di Patologia molecolare del Centro Fibrosi Cistica dell'Ospedale di Verona, ha lavorato sulla malattia genetica fibrosi cistica studiando in particolare gli effetti delle mutazioni nonsense sul difetto di espressione del gene CFTR (cfr. *J Clin Invest.* 1993;92:2683) e sulla regolazione della funzione della proteina CFTR, e ottenendo l'identificazione originale del ruolo della protein chinasi C nella attivazione della funzione di trasporto del cloro della proteina CFTR (cfr. *J Biol Chem.* 1993;268:11321).

Dal 1992, ha sviluppato progetti di ricerca sul trasferimento del gene CFTR in cellule epiteliali bronchiali fibrocistiche, utilizzando vettori genici di derivazione virale difettivi per la replicazione. In questa linea di ricerca ha messo a punto un sistema di analisi della funzione di CFTR in singola cellula epiteliale respiratoria per verificare la correzione del difetto genetico di base, utilizzando una molecola sensibile al potenziale di membrana (Progetto Telethon, cfr. *Hum Gene Ther* 1995;6:1275). Questa molecola, ed il relativo sistema di analisi, sono stati successivamente applicati con successo dalle aziende farmaceutiche implementandolo per lo screening a vasta scala di librerie di molecole chimiche per la identificazione di potenziatori e correttori della proteina CFTR difettosa (vedi *High-Throughput Screening* di Vertex Pharma, Van Goor, *Am J Physiol Lung Cell Mol Physiol* 2006;290, L1117). A fronte della scarsa efficienza del trasferimento genico verificato assieme a molti gruppi coinvolti nel campo, allo scopo di chiarire le basi molecolari della interazione di vettori virali con le cellule epiteliali bronchiali, ha guidato il suo gruppo di ricerca alla identificazione innovativa del secondo recettore utilizzato dall' adenovirus di tipo 2/5 per l'infezione di cellule eucariote (Progetto Telethon, cfr. *J Virol* 2001;75:8772). Parallelamente, a fronte della risposta immunitaria evocata dai vettori virali per trasferimento genico, ha sviluppato studi sui meccanismi della interazione patogeno-ospite, studiando la risposta pro-infiammatoria degli adenovirus tipo 2/5 a seguito di interazione con cellule respiratorie umane, a partire dai recettori ed il segnale transmembrana sino alla definizione dei principali meccanismi di regolazione della espressione di geni coinvolti nella infiammazione (cfr. *J Virol* 2006;80: 11241).

Dal 2001, con la precipua collaborazione di Gruppi di Ricerca dell'Università di Ferrara, ha concentrato il suo interesse sulla infiammazione polmonare in fibrosi cistica, per identificare nuovi bersagli molecolari di cure innovative e nuove molecole, sia per correggere la proteina CFTR difettosa sia per regolare la eccessiva infiammazione polmonare, salvaguardando la risposta immunitaria anti-infettiva. Speciale attenzione è stata rivolta alla sovraespressione della chemochina dei neutrofilo CXCL8/IL-8, una caratteristica peculiare della patologia polmonare in fibrosi cistica, della quale ha contribuito a ricostruire una mappa del segnale transmembrana coinvolto nella sua attivazione in cellule epiteliali bronchiali della fibrosi cistica (cfr. *J Immunol.* 2011;187:6069). In questo campo della ricerca è stato co-inventore della scoperta della molecola anti-infiammatoria 4,6,4'-trimethylangelicin, che presenta altresì la interessante ed innovativa proprietà di duplice azione come potenziatore e correttore della proteina CFTR recante la più comune mutazione F508del CFTR (cfr Collawn JF. *Am J Physiol Lung Cell Mol Physiol.* 2014;307:L431). La molecola è stata inclusa nel 2013 come Farmaco Orfano per la fibrosi cistica dalla European Medicines Agency (EMA).

Dal 2010, ha esteso il suo interesse scientifico ai tumori maligni del cervello, principalmente ai gliomi, con attenzione particolare alla modulazione epigenetica, quali metilazione e regolazione microRNA-dipendente, della espressione di geni rilevanti per la risposta terapeutica di prima e seconda linea nei pazienti affetti. Al momento attuale sta trasferendo le informazioni scientifiche di base per mettere a punto strumenti di identificazione della presenza di glioma, della sua progressione e recidiva, mediante analisi di biomarcatori molecolari (microRNA) in esosomi isolati dal sangue periferico, e di individuazione di biomarcatori del tessuto cerebrale neoplastico in grado di fornire predizione della efficacia della terapia a bersaglio di seconda linea in pazienti affetti da glioblastoma.

Progetti di ricerca (con finanziamento privato)

con i ruoli di Coordinatore di progetto multicentrico, Responsabile scientifico, Partner o Collaboratore:

- 1) Italian Cystic Fibrosis Research Foundation. FFC #3/2016 MicroRNA therapeutics in CF: targeting CFTR and inflammation networks. 01/09/2016 – 31/08/2017
- 2) Italian Cystic Fibrosis Research Foundation FFC #1/2016 New generation trimethylangelicin (TMA) analogues for selective modulation of defective CFTR or inflammation 01/09/2016 – 31/08/2018
- 3) Italian Cystic Fibrosis Research Foundation FFC #22/2015 A systematic investigation of miglustat-derivative iminosugars clusters as possible anti-inflammatory agents for cystic fibrosis lung disease 01/09/2015 – 31/08/2017
- 4) Italian Cystic Fibrosis Research Foundation FFC #20/2015 Mitochondrial quality control machinery a role in the P.aeruginosa-triggered inflammatory response in cystic fibrosis 01/09/2015 – 31/08/2017
- 5) Italian Cystic Fibrosis Research Foundation FFC #9/2015 Identification of molecular targets to reduce the side effect of gating potentiators on the F508del-CFTR plasma membrane stability 01/09/2015 – 31/08/2017
- 6) Italian Cystic Fibrosis Research Foundation FFC #28/2014 *In vitro* study of potential pro-fibrotic effect of everolimus in different human airway cell lines. Searching for new biomarkers to optimize MTOR-inhibitor immunosuppressive treatment of cystic fibrosis patients undergoing lung transplantation 01/09/2014 – 31/08/2016
- 7) Italian Cystic Fibrosis Research Foundation FFC #24/2014 The role of GBA2 in cystic fibrosis lung

inflammation:from molecular mechanism to therapeutic strategies 01/09/2014 – 31/08/2016

8) Italian Cystic Fibrosis Research Foundation FFC #19/2014 Mitochondrial Ca²⁺ dependent inflammasome activation exacerbates the *P.aeruginosa*-driven inflammatory response 01/09/2014 – 31/08/2016

9) Italian Cystic Fibrosis Research Foundation FFC #17/2014 TRPA1 channels as novel targets for anti-inflammatory therapies in CF lung 01/09/2014 – 31/08/2016

10) Italian Cystic Fibrosis Research Foundation FFC #8/2014 Design and synthesis of improved analogs of TMA for personalized treatment of cystic fibrosis 01/09/2014 – 31/08/2015

11) Italian Cystic Fibrosis Research Foundation FFC #1/2013 Mechanisms of action of trimethyl angelicin in rescuing F508del CFTR functional expression Durata: 01/09/2013 – 31/08/2015

12) Italian Cystic Fibrosis Research Foundation FFC #14/2012 Structure-activity relationships (SAR) of neoglycoconjugates derived from deoxynojirimycin as possible therapeutic agents for Cystic Fibrosis lung disease, by modulating the metabolism of sphingolipids 01/09/2012 – 31/08/2014

13) Italian Cystic Fibrosis Research Foundation FFC #1/2012 The read-through approach for the treatment of cystic fibrosis caused by premature termination codons 01/09/2012 – 31/08/2014

14) Italian Cystic Fibrosis Research Foundation FFC #19/2011 Phospholipase C beta (PLCB) as candidate therapeutic target in CF lung proinflammatory signaling 01/09/2011 – 31/08/2013

15) Italian Cystic Fibrosis Research Foundation FFC #5/2011 European Cystic Fibrosis Modifier Gene Study 01/09/2011 – 31/08/2014

16) Italian Cystic Fibrosis Research Foundation FFC #1/2011 Properties of trimethylangelicin in F508del CFTR rescue 01/09/2011 – 31/08/2013

17) Italian Cystic Fibrosis Research Foundation FFC #17/2010 Molecular characterization of trimethylangelicin (TMA) and structurally-related compounds in CF lung disease: anti-inflammatory effects and potentiation of the CFTR biological activity 01/09/2010 – 31/08/2012

18) Italian Cystic Fibrosis Research Foundation FFC #16/2010 Modulation of sphingolipid metabolism as a strategy for the treatment of CF lung inflammation 01/09/2010 – 31/08/2012

19) Italian Cystic Fibrosis Research Foundation FFC #12/2010 Calcium signaling and PKC as targets of *Pseudomonas aeruginosa* infection 01/09/2010 – 31/08/2012

20) Italian Cystic Fibrosis Research Foundation FFC #8/2010 Decrease apical infection of CFTR by *Pseudomonas aeruginosa* infection: role of NHERF1 phosphorylation 01/09/2010 – 31/08/2011

21) Italian Cystic Fibrosis Research Foundation FFC #2/2010 Novel cellular model system and therapeutic molecules for the development of a read-through approach for CF caused by stop codon mutations of the CFTR gene 01/09/2010 – 31/08/2011

22) Italian Cystic Fibrosis Research Foundation FFC #19/2009 - Role of CFTR-Connexin interaction on PGE2 signaling and inflammation: implication for cystic fibrosis 01/09/2009 – 31/08/2011

23) Italian Cystic Fibrosis Research Foundation Project FFC #18/2009 Mapping IL-8 gene transcription machinery in bronchial epithelial cells 01/09/2009 – 31/08/2011

24) Italian Cystic Fibrosis Research Foundation Project FFC QUANTIGENE/2008 - National Service for gene expression 01/01/2008 – 31/12/2012

25) Italian Cystic Fibrosis Research Foundation Project FFC #12/2008 Anti-inflammatory effect of miglustat: sphingolipid ceramide metabolism as a therapeutic target for CF lung disease 01/09/2008 – 31/08/2010

26) Italian Cystic Fibrosis Research Foundation Project FFC #3/2008 - Genetic factors influencing pulmonary disease in Cystic Fibrosis (CF) patients 01/09/2008 – 31/08/2009

27) Italian Cystic Fibrosis Research Foundation Project FFC#13/2007 A gene-targeted anti-inflammatory approach based on the Transcription Factor "decoy" strategy 01/09/2007 – 31/08/2009

28) Italian Cystic Fibrosis Research Foundation Project FFC #22/2006 Genetic factors involved in the innate immunity influencing pulmonary disease in Cystic Fibrosis patients 01/09/2006 – 31/08/2007

29) Italian Cystic Fibrosis Research Foundation Project FFC #16/2006 Effect of correctors of defective CFTR on the *Pseudomonas aeruginosa*-dependent inflammatory response in respiratory epithelial cells 01/09/2006 – 31/08/2008

30) Italian Cystic Fibrosis Research Foundation Progetto FFC #1/2006 Novel methods of intracellular delivery of ΔF508-CFTR correctors 01/09/2006 – 31/08/2008

31) Italian Cystic Fibrosis Research Foundation Project FFC #4/2005 - Novel generation lentiviral vectors: evaluation of inflammatory potential in human respiratory cells. 01/09/2005 – 31/08/2006

32) Cariverona Foundation Call 2005 – A molecular biosensor of the immunity in the airway tract: application to safety of innovative therapies in cystic fibrosis 01/01/2006 – 31/12/2008

33) Italian Cystic Fibrosis Research Foundation Project FFC #14/2004 - Interaction in vitro between cystic fibrosis pathogens and epithelial cells expressing the cystic fibrosis transmembrane conductance regulator (CFTR). 01/09/2004 – 31/08/2006

34) Italian Cystic Fibrosis Research Foundation Project FFC #4/2004 - Role of Adenovirus Receptors in the activation of Mitogen-Activated Proteins Kinase pathways and Nuclear Factor - κB in human airways epithelial cells. 01/09/2004 – 31/08/2005

35) Italian Cystic Fibrosis Research Foundation Project FFC #1/2004 - Dissection of folding/defolding processes in CFTR and DF508 CFTR. Use of disarmed toxins to target chaperones and assist refolding and expression of DF508 CFTR. 01/09/2004 – 31/08/2005

36) Telethon Foundation Call 1999 – Research area 2.3 (Advanced research on gene therapy) Project A.153 Interactions of subgroup C adenoviruses with cell receptors. Relevance to targeting and efficiency of adenovirus-derived vectors 01/09/1999 – 31/08/2001

37) Telethon Foundation Call 1993 – Research area 2.3 (Research on gene therapy) Project A.04 Gene therapy of cystic fibrosis in airway cells: functional expression of the gene by viral vectors 01/09/1993 – 31/08/1994

Ruoli in Comitati e Società scientifiche (ultimi 10 anni)

- Componente, Commissione permanente per la Ricerca Pre-clinica e Clinica, Società Italiana Fibrosi Cistica (SIFC) (dal 2017 - oggi)

- Coordinatore, Gruppo di Lavoro sulla Infiammazione, Società Italiana Fibrosi Cistica (SIFC) (2007-2017)

- Componente, *Advisory Scientific Board of Centre de Recherche Saint-Antoine, Université Pierre et Marie Curie/INSERM, Paris, F* (dal 2016 - oggi)

- Componente, Comitato Tecnico Scientifico CORIS - *Consorzio Ricerca Sanitaria* - Università di Padova e Azienda Ospedaliera di Padova, IT (dal 2016 - oggi)

- Componente, Comitato Scientifico *Brain Research Foundation* - Verona, IT (dal 2016 - oggi)

- Componente, *Working Group on Modifier Genes* European Society for Cystic Fibrosis (2011 - 2017)

- Componente Gruppo di Lavoro "Programma Ricerca ed Innovazione - *Health Technology Assessment* (PRIHTA) Regione Veneto, Venezia, IT (2011-2015)

- Componente "Nucleo Ricerca ed Innovazione" Azienda Ospedaliera Universitaria Integrata (*University Hospital*) Verona, IT (2009-2015)

Attività di revisione scientifica (ultimi 10 anni)

Editorial Board of Reviewers *Frontiers in Pharmacology* sezioni

- *Pharmacology of Ion Channels and Channelopathies* (from 2013)

- *Respiratory Pharmacology* (from 2015)

Revisore *ad hoc* di riviste scientifiche internazionali (ultimi 10 anni)

Human Gene Therapy, European Respiratory Journal, The Journal of Leukocyte Biology, Clinical Chemistry, The Journal of Biological Chemistry, Molecular Therapy, Human Mutations, Journal of Neurochemistry, PlosOne, Frontiers in Immunology, Frontiers in Pharmacology, European Journal of Pharmacology, Experimental Lung Research, American Journal of Respiratory and Critical Care Medicine, Frontiers in Immunology, Current Medicinal Chemistry, Oncotarget.

Attività di revisione di progetti sottoposti per il finanziamento (ultimi 10 anni)

per conto di Società scientifiche oppure Fondazioni di ricerca:

- Consorzio Italiano Interuniversitario Biotecnologie CIB (Rome, IT)

- Cystic Fibrosis Trust (London, UK).

- University of California (San Diego, CA, USA)

- Swiss Science Foundation (Geneve, CH)

- AFM-Telethon (Paris, F)

- Irish Thoracic Society (Dublin, IR)

Attività didattica

con incarichi ufficiali di Professore a contratto:

- Università di Ferrara, IT - "Patologia cellulare recettoriale" - DU Tecnici Laboratorio Biomedico ('95-96)

- Università di Verona, IT - "Patologia Generale" - DU Scienze Infermieristiche ('96-97)

- Università di Verona, IT - "Patologia Generale" - DU Infermiere (from '96 to 2001)

- Università di Verona, IT - "Patologia Generale" - DU Ostetriche (from '96 to 2001)

- Università di Verona, IT - "Biologia molecolare" - Scuola Specializzazione Biochimica Clinica (2000-01)

- Università di Verona, IT - "Patologia Generale" - Facoltà Medicina/School of Medicine - CdL Tecniche Laboratorio Biomedico (from 2004 to 2017)

GC ha ottenuto l'Abilitazione Scientifica Nazionale (Bando ASN 2012) in MED/04 Patologia generale e Patologia Clinica (2^a fascia)

GC è stato Tutor di diversi studenti iscritti alle Università di Ferrara, Verona, Bologna, San Raffaele Vita e Salute (Milano) per Tesi di Laurea triennale e specialistica, specializzazioni post-laurea e Dottorato di Ricerca.

Brevetti

1) Effetto anti-infiammatorio del miglustat su cellule dell'epitelio bronchiale.

Inventors: DECHECCHI Maria Cristina, BORGATTI Monica, TAMANINI Anna, LAMPRONTI Ilaria, NICOLIS Elena, Mancini Irene, BezzeRri Valentino, MAZZI Paola, RIZZOTTI Paolo, BERTON Giorgio, GAMBARI Roberto, CABRINI Giulio.

Italian Patent filed # FE2008A000032

2) Effetto anti-infiammatorio di trimetil-angelicina su cellule dell'epitelio bronchiale.

Inventors: TAMANINI Anna, BORGATTI Monica, DECHECCHI Maria Cristina, LAMPRONTI Ilaria, NICOLIS Elena, Mancini Irene, BezzeRri Valentino, RIZZOTTI Paolo, CABRINI Giulio, GAMBARI Roberto.

Italian Patent filed # FE2008A000033

3) Nuovo uso della trimetil-angelicina come correttore di CFTR in cellule dell'epitelio bronchiale

Inventors: CABRINI Giulio, CASAVOLA Valeria, GAMBARI Roberto.

2011 Italian Patent filed # MI2011A0001009

4) 2016 United States Patent No. US 9.183.206 B2 March 15, 2016

TRIMETHYLANGELICIN AS CFTR CORRECTOR IN BRONCHIAL EPITHELIAL CELLS

Inventors: CABRINI Giulio, CASAVOLA Valeria, GAMBARI Roberto.

Assignees: Azienda Ospedaliera Universitaria Integrata di Verona, Verona (IT), Università degli Studi di Ferrara, Ferrara (IT), Università degli Studi di Bari Bari (IT), Rare Partners S.r.l., Milano (IT)

Presentazioni scientifiche (selezione ultimi 10 anni)

GC è stato invitato a tenere letture, presentazioni orali e relazioni, o a presiedere sessioni congressuali in diversi Convegni Internazionali e Nazionali e presso Università e Istituti di Ricerca:

- [European Cystic Fibrosis Conference – New Frontiers in Basic Science of Cystic Fibrosis – Douro, Portugal, 2008](#)

Symposium 5 –Inflammation and other respiratory responses in CF

Oral presentation: Identification of anti-inflammatory potential of *Aegle marmelos* by screening medicinal plant extracts.

- [CIB- Consorzio Interuniversitario Biotecnologie - PhD School, Ferrara, IT 2008](#)

Oral presentation: *Transcription factor decoy molecules in cystic fibrosis*

- [European Cystic Fibrosis Conference – New Frontiers in Basic Science of Cystic Fibrosis – Tavira, Portugal, 2009](#)

Co-chairperson Symposium 7 – Inflammation in Cystic Fibrosis (with T. Bonfield, U.S.A.)

Co-chairperson Special Group Discussion III – Modifier genes – what have we learnt ? (with M. Drumm, U.S.A.)

- [European Cystic Fibrosis Society – New Frontiers in Basic Science of Cystic Fibrosis – Carcavelos, Portugal, 2010](#)

Invited speaker: Pharmacological modulation of chemotactic signalling in CF respiratory models.

- [European Cystic Fibrosis Conference – New Frontiers in Basic Science of Cystic Fibrosis – Carcavelos, Portugal, 2010](#)

Co-chairperson Symposium 5 – Inflammatory signalling in CF lung disease (with A. Mehta, U.K.)

- [European Cystic Fibrosis Conference – New Frontiers in Basic Science of Cystic Fibrosis – Pisa, IT, 2011](#)

Co-chairperson Symposium 5 – Inflammatory mechanisms in CF as therapeutic targets (with B. Scholte, NL) and

Invited speaker: *Modulating chemotactic signaling: novel molecular targets*

- [26th Annual North American Cystic Fibrosis Conference - Orlando, Florida 2012](#)

Workshop Session. APP/AD: Inflammation, oxidants and cytokines (Research).

Invited speaker: Introductory overview on inflammation and redox in CF lung pathology.

- [Institute Pasteur - Innate host defence and inflammation Unit - Paris, F, 2013](#)

Seminar: Regulation of expression of IL-8 gene induced by *P.aeruginosa* in epithelial cells: the model of cystic fibrosis lung disease

- [European CF Conference - New Frontiers in Basic Science of Cystic Fibrosis – Malaga, Spain, 2013](#)

Co-chairperson Symposium: Infection, inflammation and immunity (with M. Chignard, Paris, F)

- [European Cystic Fibrosis Society – New Frontiers in Basic Science of Cystic Fibrosis – Malaga, Spain, 2013](#)

Invited speaker: Phospholipase C beta and pro-inflammatory signalling in bronchial epithelial cells.

- [European CF Society – New Frontiers in Basic Science of Cystic Fibrosis – St. Julians, Malta, 2014](#)

Invited speaker: *P. aeruginosa* and modulation of IL-8 gene expression in bronchial epithelial cells

- [European CF Conference - New Frontiers in Basic Science of Cystic Fibrosis - Pisa, Italy 2016](#)

Co-chairperson Symposium: Therapeutic approaches (with M. Amaral, Lisboa, PT)

- European Cystic Fibrosis Society –Basic Science Conference - Pisa, Italy, 2016

Invited speaker: Intracellular calcium mobilization as amplifier of the inflammatory response in CF bronchial epithelial cells.

- IRCSS Istituto Neurologico "Carlo Besta" - Ciclo aggiornamenti in neuro-oncologia - Milano 2017

Seminar: Epigenetics of gliomas

- Italian National research Council (CNR) - Institute of Protein Biochemistry - Napoli 2017

Seminar: Inflammatory response in cystic fibrosis lungs: in search of druggable targets.

Articoli in extenso pubblicati su riviste internazionali indicizzate (selezione)

Gli asterischi sul nome evidenziano gli articoli pubblicati nei quali GC è stato ricercatore responsabile (*senior author*)[**], autore responsabile della corrispondenza [**] o ricercatore co-responsabile (*co-senior author*) [*]

Rimessi A, Bezzerri V, Salvatori F, Tamanini A, Nigro F, Dececchi MC, Santangelo A, Prandini P, Munari S, Provezza L, Garreau de Loubresse N, Muller J, Ribeiro CMP, Lippi G, Gambari R, Pinton P, **Cabrini G****. PLCB3 Loss-of-function Reduces *P. aeruginosa*-dependent IL-8 Release in Cystic Fibrosis. *Am J Respir Cell Mol Biol*. 2018 Apr 18. [Epub ahead of print]

Marzaro G, Lampronti I, D'Aversa E, Sacchetti G, Miolo G, Vaccarin C, **Cabrini G**, Dececchi MC, Gambari R, Chilin A. Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB). *Eur J Med Chem*. 2018;151:285-293.

Schiumarini D, Loberto N, Mancini G, Bassi R, Giussani P, Chiricozzi E, Samarani M, Munari S, Tamanini A, **Cabrini G**, Lippi G, Dececchi MC, Sonnino S, Aureli M. Evidence for the Involvement of Lipid Rafts and Plasma Membrane Sphingolipid Hydrolases in *Pseudomonas aeruginosa* Infection of Cystic Fibrosis Bronchial Epithelial Cells. *Mediators Inflamm*. 2017;2017:1730245.

Fabbi E, Tamanini A, Jakova T, Gasparello J, Manicardi A, Corradini R, Sabbioni G, Finotti A, Borgatti M, Lampronti I, Munari S, Dececchi MC, **Cabrini G**, Gambari R. A Peptide Nucleic Acid against MicroRNA miR-145-5p Enhances the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells. *Molecules*. 2017;23: E71.

Lampronti I, Manzione MG, Sacchetti G, Ferrari D, Spisani S, Bezzerri V, Finotti A, Borgatti M, Dececchi MC, Miolo G, Marzaro G, **Cabrini G**, Gambari R, Chilin A. Differential Effects of Angelicin Analogues on NF-kB Activity and IL-8 Gene Expression in Cystic Fibrosis IB3-1 Cells. *Mediators Inflamm*. 2017;2017:2389487.

Santangelo A, Imbrucè P, Gardenghi B, Belli L, Agushi R, Tamanini A, Munari S, Bossi AM, Scambi I, Benati D, Mariotti R, Di Gennaro G, Sbarbati A, Eccher A, Ricciardi GK, Ciceri EM, Sala F, Pinna G, Lippi G, **Cabrini G***, Dececchi MC. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. *J Neurooncol*. 2018;136:51-62.

Santangelo A, Tamanini A, **Cabrini G***, Dececchi MC. Circulating microRNAs as emerging non-invasive biomarkers for gliomas. *Ann Transl Med*. 2017;5:277. Review.

Lampronti I, Dececchi MC, Rimessi A, Bezzerri V, Nicolis E, Guerrini A, Tacchini M, Tamanini A, Munari S, D'Aversa E, Santangelo A, Lippi G, Sacchetti G, Pinton P, Gambari R, Agostini M, **Cabrini G****. β -Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells. *Front Pharmacol*. 2017;8:236.

Brunelli M, Eccher A, Cima L, Trippini T, Pedron S, Chilosi M, Barbareschi M, Scarpa A, Pinna G, **Cabrini G**, Pilotto S, Carbognin L, Bria E, Tortora G, Fioravanzo A, Schiavo N, Meglio M, Sava T, Belli L, Martignoni G, Ghimenton C. Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. *Cancer Genet*. 2017;210:28-33.

- Montagner G, Bezzerri V, **Cabrini G**, Fabbri E, Borgatti M, Lampronti I, Finotti A, Nielsen PE, Gambari R. An antisense peptide nucleic acid against *Pseudomonas aeruginosa* inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system. *Int J Biol Macromol*. 2017;99:492-498.
- Prandini P, De Logu F, Fusi C, Provezza L, Nassini R, Montagner G, Materazzi S, Munari S, Gilioli E, Bezzerri V, Finotti A, Lampronti I, Tamanini A, Dececchi MC, Lippi G, Ribeiro CM, Rimessi A, Pinton P, Gambari R, Geppetti P, **Cabrini G****. Transient Receptor Potential Ankyrin 1 Channels Modulate Inflammatory Response in Respiratory Cells from Patients with Cystic Fibrosis. *Am J Respir Cell Mol Biol*. 2016;55:645-656.
- Aureli M, Schiumarini D, Loberto N, Bassi R, Tamanini A, Mancini G, Tironi M, Munari S, **Cabrini G**, Dececchi MC, Sonnino S. Unravelling the role of sphingolipids in cystic fibrosis lung disease. *Chem Phys Lipids*. 2016 ;200:94-103.
- Brogna E, Fabbri E, Montagner G, Gasparello J, Manicardi A, Corradini R, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Lampronti I, Milani R, Dececchi MC, **Cabrini G**, Gambari R. High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222. *Int J Oncol*. 2016;48:1029-38.
- Cigana C, Lorè NI, Riva C, De Fino I, Spagnuolo L, Sipione B, Rossi G, Nonis A, **Cabrini G**, Bragonzi A. Tracking the immunopathological response to *Pseudomonas aeruginosa* during respiratory infections. *Sci Rep*. 2016;6:21465.
- Fabbri E, Montagner G, Bianchi N, Finotti A, Borgatti M, Lampronti I, **Cabrini G**, Gambari R. MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. *Oncol Rep*. 2016;35:2866-72.
- Khalil S, Fabbri E, Santangelo A, Bezzerri V, Cantù C, Di Gennaro G, Finotti A, Ghimenton C, Eccher A, Dececchi M, Scarpa A, Hirshman B, Chen C, Ferracin M, Negrini M, Gambari R, **Cabrini G****. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. *Oncotarget*. 2016;7:28195-206.
- Aureli M, Schiumarini D, Loberto N, Bassi R, Tamanini A, Mancini G, Tironi M, Munari S, **Cabrini G**, Dececchi MC, Sonnino S. Unravelling the role of sphingolipids in cystic fibrosis lung disease. *Chem Phys Lipids*. 2016;200:94-103.
- Prandini P, De Logu F, Fusi C, Provezza L, Nassini R, Montagner G, Materazzi S, Munari S, Gilioli E, Bezzerri V, Finotti A, Lampronti I, Tamanini A, Dececchi MC, Lippi G, Ribeiro CM, Rimessi A, Pinton P, Gambari R, Geppetti P, **Cabrini G****. Transient Receptor Potential Ankyrin 1 Channels Modulate Inflammatory Response in Respiratory Cells from Patients with Cystic Fibrosis. *Am J Respir Cell Mol Biol*. 2016;55:645-656.
- Fabbri E, Brogna E, Montagner G, Ghimenton C, Eccher A, Cantù C, Khalil S, Bezzerri V, Provezza L, Bianchi N, Finotti A, Borgatti M, Moretto G, Chilosi M, **Cabrini G****, Gambari R. Regulation of IL-8 gene expression in gliomas by microRNA miR-93. *BMC Cancer*. 2015;15:661.
- Cabrini G****, Fabbri E, Lo Nigro C, Dececchi MC, Gambari R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). *Int J Oncol*. 2015;47:417-28.
- Rimessi A, Bezzerri V, Patergnani S, Marchi S, **Cabrini G***, Pinton P. Mitochondrial Ca²⁺-dependent NLRP3 activation exacerbates the *Pseudomonas aeruginosa*-driven inflammatory response in cystic fibrosis. *Nat Commun*. 2015 Feb 4;6:6201.
- Bezzzerri V, Avitabile C, Dececchi MC, Lampronti I, Borgatti M, Montagner G, **Cabrini G**, Gambari R, Romanelli A. Antibacterial and anti-inflammatory activity of a temporin B peptide analogue on an in vitro model of cystic fibrosis. *J Pept Sci*. 2014;20:822-30.

- Loberio N, Tebon M, Lampronti I, Marchetti N, Aureli M, Bassi R, Giri MG, Bezzerri V, Lovato V, Cantù C, Munari S, Cheng SH, Cavazzini A, Gambari R, Sonnino S, **Cabrini G**, Dechecchi MC. GBA2-encoded β -glucosidase activity is involved in the inflammatory response to *Pseudomonas aeruginosa*. *PLoS One*. 2014;9:e104763.
- Favia M, Mancini MT, Bezzerri V, Guerra L, Laselva O, Abbattiscianni AC, Debellis L, Reshkin SJ, Gambari R, **Cabrini G***, Casavola V. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. *Am J Physiol Lung Cell Mol Physiol*. 2014;307:L48-61.
- Rubino R, Bezzerri V, Favia M, Facchini M, Tebon M, Singh AK, Riederer B, Seidler U, Iannucci A, Bragonzi A, **Cabrini G**, Reshkin SJ, Tamanini A. *Pseudomonas aeruginosa* reduces the expression of CFTR via post-translational modification of NHERF1. *Pflugers Arch*. 2014;466:2269-78
- Brognara E, Fabbri E, Bazzoli E, Montagner G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R, Bezzerri V, **Cabrini G**, Gambari R. Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. *J Neurooncol*. 2014;118:19-28.
- Fabbri E, Borgatti M, Montagner G, Bianchi N, Finotti A, Lampronti I, Bezzerri V, Dechecchi MC, **Cabrini G**, Gambari R. Expression of microRNA-93 and Interleukin-8 during *Pseudomonas aeruginosa*-mediated induction of proinflammatory responses. *Am J Respir Cell Mol Biol*. 2014;50:1144-55.
- Finotti A, Borgatti M, Bezzerri V, Nicolis E, Lampronti I, Dechecchi M, Mancini I, **Cabrini G**, Saviano M, Avitabile C, Romanelli A, Gambari R. Effects of decoy molecules targeting NF-kappaB transcription factors in Cystic fibrosis IB3-1 cells: recruitment of NF-kappaB to the IL-8 gene promoter and transcription of the IL-8 gene. *Artif DNA PNA XNA*. 2012;3:97-296.
- Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, **Cabrini G****; Working Group on Inflammation in Cystic Fibrosis. Oxidative stress and antioxidant therapy in cystic fibrosis. *Biochim Biophys Acta*. 2012;1822:690-713.
- Bezzzerri V, Borgatti M, Finotti A, Tamanini A, Gambari R, **Cabrini G****. Mapping the transcriptional machinery of the IL-8 gene in human bronchial epithelial cells. *J Immunol*. 2011;187:6069-81.
- Dechecchi MC, Nicolis E, Mazzi P, Cioffi F, Bezzerri V, Lampronti I, Huang S, Wiszniewski L, Gambari R, Scupoli MT, Berton G, **Cabrini G****. Modulators of sphingolipid metabolism reduce lung inflammation. *Am J Respir Cell Mol Biol*. 2011;45:825-33.
- Bezzzerri V, d'Adamo P, Rimessi A, Lanzara C, Crovella S, Nicolis E, Tamanini A, Athanasakis E, Tebon M, Bisoffi G, Drumm ML, Knowles MR, Pinton P, Gasparini P, Berton G, **Cabrini G****. Phospholipase C- β 3 Is a Key Modulator of IL-8 Expression in Cystic Fibrosis Bronchial Epithelial Cells. *J Immunol*. 186, 4946-58, 2011.
- Tamanini A, Borgatti M, Finotti A, Piccagli L, Bezzerri V, Favia M, Guerra L, Lampronti I, Bianchi N, Dall'acqua F, Vedaldi D, Salvador A, Fabbri E, Mancini I, Nicolis E, Casavola V, **Cabrini G*/****, Gambari R. Trimethylangelicin Reduces IL-8 Transcription and Potentiates CFTR Function. *Am J Physiol Lung Cell Mol Physiol*. 300, L380-90, 2011
- Crovella S, Segat L, Amato A, Athanasakis E, Bezzerri V, Braggion C, Casciaro R, Castaldo G, Colombo C, Covone AE, De Rose V, Gagliardini R, Lanzara C, Minicucci L, Morgutti M, Nicolis E, Pardo F, Quattrucci S, Raia V, Ravazzolo R, Seia M, Stanzial V, Termini L, Zazzeron L, **Cabrini G**, Gasparini P. A polymorphism in the 5' UTR of the DEFB1 gene is associated with the lung phenotype in F508del homozygous Italian cystic fibrosis patients. *Clin Chem Lab Med*. 49, 49-54, 2011
- Piccagli L, Borgatti M, Nicolis E, Bianchi N, Mancini I, Lampronti I, Vedaldi D, Dall'Acqua F, **Cabrini G**, Gambari R. Virtual screening against nuclear factor κ B (NF- κ B) of a focus library: Identification of bioactive furocoumarin derivatives inhibiting NF- κ B dependent biological functions involved in cystic fibrosis.

Cabrini G, Bezzerri V, Mancini I, Nicolis E, Dececchi MC, Tamanini A, Lampronti I, Piccagli L, Bianchi N, Borgatti M, Gambari R. Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds.
Curr Med Chem. 17, 4392-404, 2010

Gambari R, Borgatti M, Bezzerri V, Nicolis E, Lampronti I, Dececchi MC, Mancini I, Tamanini A, **Cabrini G**. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with *Pseudomonas aeruginosa*.
Biochem Pharmacol. 80, 1887-94, 2010

Piccagli L, Fabbri E, Borgatti M, Bianchi N, Bezzerri V, Mancini I, Nicolis E, Dececchi CM, Lampronti I, **Cabrini G**, Gambari R. Virtual screening against p50 NF-kappaB transcription factor for the identification of inhibitors of the NF-kappaB-DNA interaction and expression of NF-kappaB upregulated genes.
ChemMedChem. 4, 2024-33, 2009

Nicolis E, Lampronti I, Dececchi MC, Borgatti M, Tamanini A, Bezzerri V, Bianchi N, Mazzon M, Mancini I, Giri MG, Rizzotti P, Gambari R, **Cabrini G****. Modulation of expression of IL-8 gene in bronchial epithelial cells by 5-methoxypsoralen.
Int Immunopharmacol. 9, 1411-22, 2009

Copreni E, Nicolis E, Tamanini A, Bezzerri V, Castellani S, Palmieri L, Giri MG, Vella A, Colombatti M, Rizzotti P, Conese M, **Cabrini G****. Late generation lentiviral vectors: evaluation of inflammatory potential in human airway epithelial cells.
Virus Res. 144, 8-17, 2009.

Dececchi MC, Nicolis E, Norez C, Bezzerri V, Borgatti M, Mancini I, Rizzotti P, Ribeiro CM, Gambari R, Becq F, **Cabrini G****. Anti-inflammatory effect of miglustat in bronchial epithelial cells.
J Cyst Fibros. 7, 555-65, 2008

Piccagli L, Fabbri E, Borgatti M, Bezzerri V, Mancini I, Nicolis E, Dececchi MC, Lampronti I, **Cabrini G**, Gambari R. Docking of molecules identified in bioactive medicinal plants extracts into the p50 NF-kappaB transcription factor: correlation with inhibition of NF-kappaB/DNA interactions and inhibitory effects on IL-8 gene expression.
BMC Struct Biol. 8, 38, 2008

Nicolis E, Lampronti I, Dececchi MC, Borgatti M, Tamanini A, Bianchi N, Bezzerri V, Mancini I, Giri MG, Rizzotti P, Gambari R, **Cabrini G****. Pyrogallol, an active compound from the medicinal plant *Emblca officinalis*, regulates expression of pro-inflammatory genes in bronchial epithelial cells.
Int Immunopharmacol. 8, 1672-80, 2008

Norez C, Pasetto M, Dececchi MC, Barison E, Anselmi C, Tamanini A, Quiri F, Cattel L, Rizzotti P, Dosio F, **Cabrini G***, Colombatti M. Chemical conjugation of DeltaF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions.
Am J Physiol Lung Cell Mol Physiol. 295, L336-47, 2008

Bezzzerri V, Borgatti M, Nicolis E, Lampronti I, Dececchi MC, Mancini I, Rizzotti P, Gambari R, **Cabrini G****. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells.
Am J Respir Cell Mol Biol. 39, 86-96, 2008

Borgatti M, Bezzerri V, Mancini I, Nicolis E, Dececchi MC, Lampronti I, Rizzotti P, **Cabrini G**, Gambari R. Induction of IL-6 gene expression in a CF bronchial epithelial cell line by *Pseudomonas aeruginosa* is dependent on transcription factors belonging to the Sp1 superfamily.
Biochem Biophys Res Commun. 357, 977-83, 2007

Dececchi MC, Nicolis E, Bezzerri V, Vella A, Colombatti M, Assael BM, Mettey Y, Borgatti M, Mancini I, Gambari R, Becq F, **Cabrini G****. MPB-07 Reduces the Inflammatory Response to *Pseudomonas aeruginosa* in Cystic Fibrosis Bronchial Cells.
Am J Respir Cell Mol Biol. 36, 615-624, 2007

- Tamanini A, Nicolis E, Bonizzato A, Bezzeri V, Melotti P, Assael BM, **Cabrini G****. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells.
J Virol. 80, 11241-54, 2006
- Cabrini G****, Falzoni S, Forchap SL, Pellegatti P, Balboni A, Agostini P, Cuneo A, Castoldi G, Baricordi OR, Di Virgilio F. An His-155 to Tyr Polymorphism Confers Gain-of-function to the Human P2X7 Receptor of Human Leukemic Lymphocytes
J Immunol 175, 82-89, 2005
- Tamanini A, Rolfini R, Nicolis E, Melotti P, **Cabrini G****. MAP Kinases and NF-kB collaborate to induce ICAM-1 gene expression in the early phase of adenovirus infection.
Virology 307, 228-242, 2003
- Cabrini G****, Zanolla L. Cystic fibrosis conductance regulator and lung clearance of Pseudomonas aeruginosa. J Clin Invest, eLetter to the Editor (www.jci.org), in reference to Worlitzsch D. et al.
J Clin Invest 109, 317-325, 2002
- Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond J.-M, Mettey Y, **Cabrini G**, Fanen P, Galietta LJV. Correction of G551D-CFTR transport defect by genistein in polarized respiratory monolayers.
Brit J Pharmacol 137, 504-512, 2002
- Campello S, Tombola F, **Cabrini G**, Zoratti M. The vacuolating toxin of Helicobacter pylori mimicks the CFTR-mediated chloride conductance.
FEBS Lett 532, 237-240, 2002
- Galietta LJV, Pagesy P, Folli C, Caci E, Romio L, Costes B, Nicolis E, **Cabrini G**, Goossens M, Ravazzolo R, Zegarra-Moran O. IL-4 is a potent modulator of ion transport in the human bronchial epithelium.
J Immunol 168, 839-845, 2002
- Melotti P, Nicolis E, Tamanini A, Rolfini R, Pavirani A, and **Cabrini G****. Activation of NF-kB mediates ICAM-1 induction in respiratory cells exposed to an adenovirus-derived vector.
Gene Ther 8, 1436-1442, 2001
- Dehecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, **Cabrini G****. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5.
J Virol 75, 8772-8780, 2001
- Lerondel S, Le Pape A, Sené C, Faure L, Bernard S, Diot P, Nicolis E, Mehtali M, Lusky M, **Cabrini G**, Pavirani A. Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapy.
Hum Gene Ther 12, 1-11, 2001
- Dehecchi MC, Tamanini A, Bonizzato A, **Cabrini G****. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2 – host cell interactions.
Virology 268, 382-390, 2000
- Nicolis E, Melotti P, Tamanini A, Lusky M, Mehtali M, Pavirani A, **Cabrini G****. Quantitative detection of CFTR mRNA in gene transfer studies in human, murine and simian respiratory tissues in vitro and in vivo.
Gene Ther Mol Biol 4, 221-232, 1999
- Nicolis E, Tamanini A, Melotti P, Rolfini R, Berton G, Cassatella MA, Bout A, Pavirani A, **Cabrini G****. ICAM-1 induction in respiratory cells exposed to a replication-deficient recombinant adenovirus in vitro and in vivo.
Gene Ther 5: 131-136, 1998
- Rotoli BM, Bussolati O, Dall' Asta V, Hoffman EK, **Cabrini G**, and Gazzola GC. CFTR expression in C127 cells is associated with enhanced cell shrinkage and ATP extrusion in Cl-free medium.
Biochem Biophys Res Comm 227, 755-761, 1996
- Renier M, Tamanini A, Nicolis E, Rolfini R, Imler J.-L, Pavirani A, and **Cabrini G****. Use of a membrane potential-sensitive probe to assess biological expression of the cystic fibrosis transmembrane conductance regulator.
Hum Gene Ther 6, 1275-1233, 1995

- Bonizzato A, Bisceglia L, Marigo C, Nicolis E, Bombieri C, Castellani C, Borgo G, Zelante L, Mastella G, **Cabrini G**, Gasparini P, Pignatti PF. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from North-Eastern Italy: identification of 90 % of mutations.
Hum Genet 95, 397-402, 1995
- Russo MP, Romeo G, Devoto M, Barbujani G, **Cabrini G**, Giunta A, D'Alcamo E, Leoni G, Sangiuolo F, Magnani C, Cremonesi L, Ferrari M. Analysis of linkage disequilibrium between different cystic fibrosis mutations and three intragenic microsatellites in the Italian population.
Hum Mutat 5, 23-27, 1995
- Rotoli BM, Bussolati O, Sironi M, **Cabrini G**, Gazzola GC. CFTR protein is involved in the efflux of neutral aminoacids.
Biochem Biophys Res Comm 204, 653-658, 1994
- Laudanna C, Constantin G, Baron P, Scarpini E, Scarlato G, **Cabrini G**, Dececchi C, Rossi F, Cassatella M, Berton G. Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor- α , and interleukin-8 mRNA in human neutrophils.
J Biol Chem 269, 4021-4026, 1994
- Rolfini R, **Cabrini G****. Nonsense mutation R1162X of the cystic fibrosis transmembrane conductance regulator gene does not reduce messenger RNA expression in nasal epithelial tissue.
J Clin Invest 92, 2683-2687, 1993
- Dececchi MC, Tamanini A, Berton G, **Cabrini G****. Protein kinase C activates chloride conductance in C127 cells stably expressing the cystic fibrosis gene.
J Biol Chem 268, 11321-11325, 1993
- Melo CA, Serra C, Stoyanova V, Aguzzoli C, Faraguna D, Tamanini A, Berton G, **Cabrini G**, Baralle F. Alternative splicing of a previously unidentified CFTR exon introduces an in-frame stop codon 5' of the R region.
FEBS Lett 329, 159-162, 1993
- Gasparini P, Marigo C, Bisceglia G, Nicolis E, Zelante L, Bombieri C, Borgo G, Pignatti PF, **Cabrini G**. Screening of 62 mutations in a cohort of cystic fibrosis patients from North Eastern Italy: their incidence and clinical features of defined genotypes.
Hum Mut 2, 389-394, 1993
- Papini E, **Cabrini G**, Montecucco C. The sensitivity of cystic fibrosis cells to diptheria toxin.
Toxicon 31, 359-362, 1993
- Dececchi MC, Rolfini R, Tamanini A, Gamberi C, Berton G, **Cabrini G****. Effect of modulation of protein kinase C on the cAMP-dependent chloride conductance in T84 cells.
FEBS Lett 311, 25-28, 1992
- Placchi P, Lombardo R, Tamanini A, Brusa P, Berton G, **Cabrini G****. cAMP-dependent protein kinase inhibits the chloride conductance in apical membrane vesicles of human placenta.
J Membrane Biol 119, 25-32, 1991
- Tamanini A, Berton G, **Cabrini G****. Adenosine 3':5'-monophosphate-dependent protein kinase from human placenta: characterization of the catalytic subunit.
Enzyme 45, 97-108, 1991
- Squassoni E., **Cabrini G**., Berton G. cAMP dependent chloride conductance is not different in cystic fibrosis fibroblasts.
Life Sci 46, 1265-70, 1990
- Dececchi MC, **Cabrini G****. Chloride conductance in membrane vesicles from human placenta using a fluorescent probe. Implications for cystic fibrosis.
Biochim Biophys Acta 945, 113-120, 1988

- Dehecchi MC, Girella E, **Cabrini G**, Berton G. The Km of NADH dehydrogenase in mitochondria of cystic fibrosis fibroblast cell.
Enzyme 40, 45-50, 1988
- Cabrini G**, Illsley NP, Verkman AS. External anions regulate stilbene -sensitive proton conductance in placental brush border vesicles.
Biochemistry 25, 6300-6305, 1986
- Cabrini G**, Verkman AS. Localization of cyanine dye binding to brush border membranes by quenching of n-(9-anthroyloxy) fatty acid probes.
Biochim Biophys Acta 862, 285-293, 1986
- Cabrini G**, Verkman AS. Potential sensitive response mechanism of DiS-C3(5) in biological membranes.
J Membrane Biol 92, 171-182, 1986
- Cabrini G**, Verkman AS. Mechanism of interaction of the cyanine dye DiS-C3(5) with renal brush border vesicles.
J Membrane Biol 90, 163-175, 1986
- Berton G, Cassatella M, **Cabrini G**, Rossi F. Activation of mouse macrophages causes no changes in expression and function of phorbol diesters receptors but is accompanied by alterations in the activity and kinetic parameters of NADPH oxidase.
Immunology 54, 371-379, 1985
- Rossi F, Della Bianca V, Greskowiak M, De Togni P, **Cabrini G**. Relationship between phosphoinositide metabolism Ca²⁺ changes and respiratory burst in formyl-leucyl-phenilalanine stimulated human neutrophils. The breakdown of phosphoinositide is not involved in the rise of cytosolic free Ca²⁺.
FEBS Lett 181, 253-258, 1985
- De Togni P, **Cabrini G**, Di Virgilio F. Cyclic AMP inhibition of fMet-Leu-Phe-dependent metabolic responses in human neutrophils is not due to its effect on cytosolic calcium.
Biochem J 224, 629-635, 1984

Il sottoscritto acconsente, ai sensi del D.Lgs. 30/06/2003 n.196, al trattamento dei propri dati personali.

Il sottoscritto acconsente alla pubblicazione del presente curriculum vitae sul sito dell'Università di Ferrara